Aposense Ltd. (TASE: APOS) has added Hadassah Ein Kerem Hospital in Jerusalem and the Yitzhak Rabin Medical Center (Beilinson Hospital) to the company's Phase II clinical trials of its EarliTest brain, lung, and cervix cancer early diagnostic system.
The Israeli hospitals are part of Aposense's multicenter trial of the EarliTest product underway at ten US hospitals, including Sloan Kettering, Harvard Medical School, Mount Sinai School of Medicine, University of Pittsburgh Medical Center, and the University of Pennsylvania Medical Center. The company said that expanding the clinical trial to Israel aimed at increasing patient recruitment in the clinical trials. The company hopes to complete recruitment by the end of the year.
The EarliSense product is a molecular imaging and diagnostic system to assess tumors' response to anti-cancer treatments.
Aposense VP clinical development and regulatory affairs Dr. Miri Ben-Ami said, "We are pleased by the progress of our clinical trials, and we believe that the addition of Hadassah, Beilinson, and other Israeli hospitals will make an important contribution to the success of the trials."
Aposense's share price rose 2.4% by midday to NIS 11.85, giving a market cap of NIS 314 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 4, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011